Clinical trial
SarCNU in Treating Patients With Recurrent Malignant Glioma
NCT00036660 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00036660 |
|---|---|
| Title | SarCNU in Treating Patients With Recurrent Malignant Glioma |
| Official title | A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | SarCNU |
| Enrollment | 10 |
| Start date | Jan 10, 2002 |
| Primary completion | Apr 15, 2003 |
| Completion | Sep 22, 2008 |
| First posted | Jul 8, 2003 |
| Last update posted | Apr 6, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: